Concepedia

Shweta Kamat

SK

7

Publications

467

Citations

7

H-Index

2007

Active since

Affiliations

Pfizer (India)(Current)

UCLA Medical Center

University of California, Los Angeles

Breach Candy Hospital

Harbor–UCLA Medical Center

Shweta Kamat is an author at Pfizer (India) specializing in health sciences, antimicrobial therapy, and antimicrobial resistance.

ORCID

Top concepts

Publications per year

2007–2024

7

Publications

7

Aberrant Expression of the Insulin-Like Growth Factor-1 Receptor by T Cells from Patients with Graves’ Disease May Carry Functional Consequences for Disease Pathogenesis

Raymond S. Douglas, Andrew G. Gianoukakis, Shweta Kamat et al. · The Journal of Immunology · 2007 · 152 citations

B Cells from Patients with Graves’ Disease Aberrantly Express the IGF-1 Receptor: Implications for Disease Pathogenesis

Raymond S. Douglas, Catherine J. Hwang, Nikoo F. Afifiyan et al. · The Journal of Immunology · 2008 · 139 citations · Full text

Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018–2022

Mark G. Wise, James A. Karlowsky, Naglaa Mohamed et al. · Journal of Global Antimicrobial Resistance · 2024 · 67 citations · Full text

In vitro activity of Ceftazidime–Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019

Yamuna Devi Bakthavatchalam, Abhisek Routray, Akshata Mane et al. · Diagnostic Microbiology and Infectious Disease · 2022 · 35 citations · Full text

, , +19

In vitro activity of aztreonam–avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019–2021

Mark G. Wise, James A. Karlowsky, Naglaa Mohamed et al. · European Journal of Clinical Microbiology & Infectious Diseases · 2023 · 33 citations · Full text

Rows per page

1–5 of 7